BEFORE THE JOINT MEETING OF THE SCIENCE SUBCOMMITTEE AND THE INTELLECTUAL PROPERTY AND INDUSTRY SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION:	CLAREMONT	HOTEL
	44 TUNNEL	ROAD
	BERKELEY,	CALIFORNIA

- DATE: JUNE 14, 2016 4 P.M.
- REPORTER: BETH C. DRAIN, CSR CSR. NO. 7152
- BRS FILE NO.: 98697

INDEX

ITEM DESCRIPTION

PAGE NO.

1. CALL TO ORDER.

2. ROLL CALL.

3. DISCUSSION OF PROCESS FOR THE GRANTS WORKING GROUP REVIEW OF APPLICATIONS FOR THE ACCELERATING THERAPEUTICS THROUGH PUBLIC PRIVATE PARTNERSHIPS (ATP3) REQUEST FOR APPLICATION.

4. PUBLIC COMMENT

BARRISTERS' REPORTING SERVICE 1 BERKELEY, CALIFORNIA; TUESDAY, JUNE 14, 2016 2 4 P.M. 3 CHAIRMAN SHEEHY: HELLO. THIS IS JEFF 4 5 SHEEHY, AND I WOULD LIKE TO CALL THE JOINT MEETING OF THE SCIENCE SUBCOMMITTEE AND THE INDUSTRY IP 6 7 SUBCOMMITTEE TO ORDER. MS. BONNEVILLE, COULD YOU CALL THE ROLL. 8 9 MS. BONNEVILLE: ANNE-MARIE DULIEGE. 10 MICHEAL FRIEDMAN. DAVID HIGGINS. 11 DR. HIGGINS: HERE. 12 MS. BONNEVILLE: STEVE JUELSGAARD. BERT 13 LUBIN. SHLOMO MELMED. JOE PANETTA. 14 MR. PANETTA: HERE. 15 MS. BONNEVILLE: JEFF SHEEHY. 16 MR. SHEEHY: HERE. 17 MS. BONNEVILLE: OS STEWARD. 18 DR. STEWARD: HERE. 19 MS. BONNEVILLE: JONATHAN THOMAS. 20 CHAIRMAN THOMAS: HERE. 21 MS. BONNEVILLE: ART TORRES. 22 MR. TORRES: HERE. 23 MS. BONNEVILLE: KRISTINA VUORI. 24 DR. VUORI: HERE. 25 CHAIRMAN SHEEHY: SO I THINK WE HAVE ONE 3

1	ITEM FOR DISCUSSION, WHICH IS THE PROCESS FOR
2	EVALUATING THE ATP AWARD. SO DO WE HAVE A
3	PRESENTATION FROM CIRM, AND WHO WILL DR.
4	SAMBRANO. THANK YOU.
5	DR. SAMBRANO: THANK YOU, MR. SHEEHY. I
6	HAVE JUST BASICALLY THREE SLIDES WHICH ARE INTENDED
7	TO HIGHLIGHT THE THREE ELEMENTS THAT I THINK ARE
8	MOST PERTINENT TO THE REVIEW PROCESS FOR ATP. AND
9	I'M GOING TO JUST GO OVER EACH ONE, AND THEN WE CAN
10	COME BACK TO IT FOR EACH OF THOSE FOR DISCUSSION
11	PURPOSES. IF I COULD HAVE THE NEXT SLIDE.
12	SO THE FIRST ELEMENT IS THE SCORING
13	SYSTEM. AND WHAT I PUT ON THIS SLIDE IS ESSENTIALLY
14	WHERE WE ARE CURRENTLY IN TERMS OF OUR GRANTS
15	WORKING GROUP BYLAWS AND WHAT WE HAVE CURRENTLY
16	APPROVED, WHICH IS UTILIZING A SCORE OF ONE TO A
17	HUNDRED WITH THE FUNDING CUTOFF BEING AT 85. SO
18	ASSIGNING A OF SCORE 85 to 100 means that those are
19	APPLICATIONS WITH EXCEPTIONAL MERIT, AND THEN SCORES
20	BELOW THAT ARE THOSE THAT WOULD NOT BE RECOMMENDED
21	FOR FUNDING.
22	AND THE KEY IN COMPETITIONS WHERE
23	ESSENTIALLY WE HAVE ONE WINNER, MEANING SUCH AS ATP
24	OR THE GOAL IS TO FUND ONE ENTITY OR, AS IN THE
25	ACCELERATING CENTER WHICH WAS ALREADY REVIEWED AND
	4

¹⁶⁰ S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	WHICH WE HAVE AS AN EXAMPLE OF UTILIZING THIS
2	METHOD, AS WELL AS YOU THE CHALLENGE AWARDS, WHAT
3	HAPPENS IS THE APPLICATION THAT HAS THE HIGHEST
4	RANKING ABOVE 85 BASED ON THE AVERAGE IS THE ONE
5	THAT CARRIES THE RECOMMENDATION OF THE GRANTS
6	WORKING GROUP. BUT, OF COURSE, ALL APPLICATIONS IN
7	THEIR RANK ORDER ARE PRESENTED TO THE ICOC FOR
8	PROGRAMMATIC REVIEW AND CONSIDERATION. AND SO THAT
9	IS THE SYSTEM THAT WE HAVE FOR THAT NOW.
10	THERE ARE OBVIOUSLY OTHER WAYS IN WHICH WE
11	CAN GO ABOUT IT. THE LOGIC BEHIND UTILIZING THE ONE
12	TO A HUNDRED SYSTEM IS THAT SIMPLY IT WAS DESIGNED
13	TO COMPARE APPLICATIONS FROM ONE TO THE OTHER SUCH
14	THAT EACH REVIEWER CAN EXPRESS THEIR OWN INDIVIDUAL
15	SCORE AND WHAT THEY BELIEVE IS THE BEST AND SECOND
16	BEST APPLICATION BASED ON THE SCORE AND, THEREFORE,
17	RANK THEM.
18	WE HAVE OBVIOUSLY ANOTHER SYSTEM THAT WE
19	USE FOR CLINICAL REVIEWS WHICH USES THE 1, 2, AND 3
20	PROCESS. AND THAT ONE WAS LARGELY DESIGNED TO
21	ASSESS THE MERIT OF INDIVIDUAL PROPOSALS WHERE A 1
22	MEANS THAT IT'S READY FOR FUNDING, A 2 MEANS THAT IT
23	HAS ADDITIONAL WORK THAT CAN BE DONE AND THEN
24	RETURNS TO THE GRANTS WORKING GROUP TO CORRECT
25	DEFICIENCIES, AND A 3 MEANS IT'S NOT SOMETHING THAT
	5

1	WOULD BE FUNDED. BUT THE ONE THAT WE CURRENTLY HAVE
2	FOR THESE TYPES OF COMPETITIONS IS THE ONE TO A
3	HUNDRED AS SHOWN.
4	ON THE NEXT SLIDE, THE NEXT ELEMENT FOR
5	CONSIDERATION IS THE COMPOSITION OF THE EXPERTS THAT
6	ARE COMING TO REVIEW, IN THIS CASE, THE ATP
7	PROPOSALS. HERE OUR PROPOSAL IS THAT WE WANT TO
8	MAINTAIN THE CURRENT RULES FOR RECRUITING EXPERTS
9	FROM OUTSIDE OF CALIFORNIA RATHER THAN OPENING THE
10	MEMBERSHIP OF THE GWG TO THOSE WITHIN. WE WANT TO
11	SUPPLEMENT, OF COURSE, THE GRANTS WORKING GROUP
12	EXPERTS THAT SERVE ON THE PANEL WITH SPECIALIST
13	REVIEWERS, AS WE OFTEN DO, TO BRING IN ADDITIONAL
14	EXPERTISE WHERE THERE ARE GAPS AND WHERE IT MIGHT BE
15	NEEDED. SPECIALISTS MAY BE RECRUITED FROM WITHIN
16	CALIFORNIA, SO THAT ALLOWS US TO EXPAND OUR REACH
17	WHEN NECESSARY. AND ALSO IT ALLOWS US TO PROVIDE
18	ADDITIONAL TYPES OF EXPERTISE THAT ARE NOT NORMALLY
19	COVERED UNDER THE STATUTE OF HAVING A GRANTS WORKING
20	GROUP MEMBER THAT IS A STEM CELL EXPERT; BUT,
21	RATHER, BRINGS IN THE BUSINESS AND INDUSTRY
22	EXPERTISE THAT WILL BE NECESSARY TO REVIEW THE
23	APPLICATIONS FOR ATP3.
24	THESE REVIEWERS WHO FUNCTION AS
25	SPECIALISTS CAN PROVIDE A SUGGESTED SCORE AND
	6

1	OBVIOUSLY CONTRIBUTE TO THE DISCUSSION AND DO
2	INFLUENCE THE REVIEW, BUT NORMALLY DO NOT CONTRIBUTE
3	TO THE FINAL GRANTS WORKING GROUP AVERAGE SCORE.
4	THE TOTAL NUMBER OF REVIEWERS, HOWEVER, IS
5	SOMETHING THAT WE CAN BALANCE IN ORDER TO MAINTAIN
6	BOTH A QUORUM WHILE ALSO BEING INCLUSIVE OF
7	SPECIALISTS. WHAT I MEAN THERE IS THAT NORMALLY WE
8	HAVE UP TO 15 GRANTS WORKING GROUP MEMBERS THAT
9	SERVE IN A GIVEN REVIEW PANEL. IF WE WANT TO BRING
10	IN EXPERTS THAT FUNCTION AS SPECIALISTS WITHOUT
11	CREATING AN OVERWHELMING GROUP OF 25 OR 30, WE CAN
12	TRY TO MAINTAIN A BALANCED NUMBER OF, SAY, 10 GRANTS
13	WORKING GROUP MEMBERS WITH FIVE SPECIALISTS. THAT
14	KEEPS THE GROUP RELATIVELY SMALL IN ORDER TO HAVE A
15	GOOD, ROBUST DISCUSSION AND STILL MEET THE
16	REQUIREMENTS OF A QUORUM FOR THAT GROUP.
17	AND THEN, FINALLY, ON THE NEXT SLIDE, THE
18	OTHER ELEMENT WHICH IS IMPORTANT IS HAVING THE
19	OPPORTUNITY OF THE APPLICANT TEAMS TO PRESENT IN
20	PERSON TO THE GRANTS WORKING GROUP. AND THIS IS
21	SOMETHING THAT WE TESTED FOR THE FIRST TIME DURING
22	THE ACCELERATING CENTER REVIEW PROCESS IN WHICH
23	APPLICANT TEAMS WERE INVITED TO GIVE A PRESENTATION,
24	IN THIS CASE IT WAS 20 MINUTES, BEFORE THE GRANTS
25	WORKING GROUP TO ADDRESS THEIR VISION, THEIR OVERALL
	7

¹⁶⁰ S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	VALUE PROPOSITION OF WHAT THEY ARE BRINGING TO CIRM,
2	AND ALSO THE BUSINESS PLAN AS MIGHT BE APPLICABLE
3	UNDER THE ATP3 PROGRAM.
4	IN ADDITION TO HAVING THEM PRESENT,
5	THERE'S ALSO A PERIOD OF Q AND A THAT ALLOWED THE
6	GRANTS WORKING GROUP MEMBERS TO ASK QUESTIONS
7	DIRECTLY OF THE TEAM TO ENSURE THAT THERE WAS
8	CLARITY AND UNDERSTANDING OF THEIR PROPOSAL AND
9	THEIR INTENT AND SO THAT THEY CAN COME UP WITH AN
10	APPROPRIATE EVALUATION OF THOSE GROUPS. AND THOSE
11	ARE THE THREE AREAS THAT WE THOUGHT WERE KEY.
12	CHAIRMAN SHEEHY: SO THANK YOU, DR.
13	SAMBRANO. FOR ME PERSONALLY I HAD FOUR ISSUES, BUT
14	I THINK THEY'RE DISCRETE, SO I'LL START OFF WITH THE
15	FIRST TWO. THEY'RE KIND OF IN ORDER OF HOW YOU
16	PRESENTED THEM.
17	SO FROM MY PERSPECTIVE, I THINK A 1-2-3
18	SCORING SYSTEM WOULD BE MUCH BETTER. NO. 1, WITH
19	THE 2 THERE, THAT GIVES THE ABILITY TO FINE-TUNE THE
20	AWARD, AND THAT'S KIND OF BUILT INTO THE PROCESS.
21	THAT'S SOMETHING I THINK THOSE OF US WHO HAVE BEEN
22	ENGAGED IN THE CLINICAL PROGRAM HAVE SEEN PRODUCE.
23	THAT PROCESS HAS PRODUCED MUCH BETTER APPLICATIONS.
24	NOT ONLY DOES IT PRODUCE
25	THE OTHER POINT IS, SO HAVING THE
	8
	0

1	FINE-TUNING, WE NEED TO GET THE BEST APPLICATION.
2	WE'RE SPENDING \$75 MILLION. THIS IS THE BIGGEST
3	AWARD IN CIRM'S HISTORY. JUST A STRAIGHT UP WE'LL
4	TAKE THE HIGHEST EVEN IF THERE'S SOME FLAWS THERE
5	DOESN'T QUITE SIT SO GREAT WITH ME WHEN WE COULD
6	HAVE THE OPPORTUNITY TO FINE-TUNE THEM AND MAKE THEM
7	BETTER APPLICATIONS.
8	THE SECOND THING IS THAT ONCE SOMEONE
9	ACHIEVES A SCORING LEVEL, I THINK IT CAN BE VERY
10	CHALLENGING TO PICK BETWEEN MORE THAN ONE WINNER. I
11	THINK THE FIRST TIME AROUND WE WERE FORTUNATE THERE
12	WAS ONE CLEAR WINNER. IF THERE'S MORE THAN ONE
13	CLEAR WINNER, ESPECIALLY IN ATP, THOSE DECISIONS CAN
14	BE ARBITRARY AND COULD ACTUALLY BE INFLUENCED BY
15	PROGRAMMATIC DECISIONS. YOU COULD HAVE DIFFERENT
16	PORTFOLIOS OF PROJECTS THAT ARE PUT FORWARD, AND IT
17	JUST MAY BE THAT PERHAPS WE HAVE CARDIOVASCULAR
18	DISEASE ON ONE HAND, PERHAPS ON ANOTHER WE HAVE
19	NEUROLOGICAL DISEASE. HOW DO YOU CHOOSE BETWEEN A
20	BUCKET OF DISEASES? A POINT HERE OR A POINT THERE
21	MAKING THAT DECISION KIND OF MAKES ME UNCOMFORTABLE.
22	IN FACT, IT DOES MAKE ME UNCOMFORTABLE.
23	I THINK ONCE WE ESTABLISH THE BASELINE FOR
24	MERIT, THOSE APPLICATIONS THEN CAN COME TO THE BOARD
25	FOR A REAL DISCUSSION ON WHICH ENTITY WE ACTUALLY
	9

1	WANT TO GO INTO BUSINESS WITH. SO HAVING SOMEONE
2	WHO'S TRYING TO TEASE OUT SOMEONE WHO SCORES BETWEEN
3	85 AND 100, KNOWING THAT THERE'S PROBABLY NOT GOING
4	TO BE A 100 AND IT'S PROBABLY NOT GOING TO BE AN 85,
5	SO WE'RE PROBABLY GOING TO BE LOOKING AT SOMEBODY
6	BETWEEN 88 AND 93. I JUST THINK THOSE DIFFERENCES
7	ARE SO SMALL THAT IT'S GOING TO BE HARD TO REALLY
8	COME BECAUSE WE'LL COME TO THE BOARD WITH THESE
9	PROJECTS AND IT WILL LOOK LIKE WE HAVE AN OBLIGATION
10	TO DO THE 93, BUT THE DIFFERENCE BETWEEN THOSE IS SO
11	SMALL, WE'RE KIND OF ROBBING THE BOARD OF ITS
12	ABILITY TO MAKE A DECISION IN THIS INSTANCE. AND
13	WE'RE SETTING UP A SITUATION WHERE WE CREATE
14	DISSONANCE AND INCOHERENCE WHEN WE'RE TRYING TO
15	COMMUNICATE TO THE PUBLIC.
16	AND THEN THE OTHER PART THAT I WOULD LIKE
17	TO SEE CHANGED IN TERMS OF THE SCORING AND THE GWG
18	PROCESS, JUST STAYING ON THOSE ALTOGETHER, IS I DO
19	THINK THAT THERE SHOULD BE POSTSCORING. RIGHT NOW
20	EVERYBODY SCORES, THE SCORES FLY UP. I THINK A
21	POSTSCORING DISCUSSION OF THE HIGHEST RATED
22	APPLICATIONS IS A GOOD IDEA TO PUT INTO THE PROCESS.
23	SO DO OTHER BOARD MEMBERS HAVE THOUGHTS
24	AROUND THIS SO WE CAN KIND OF GET SOME OTHER
25	OPINIONS IN HERE? THOSE ARE TWO ISSUES. I HAVE A
	10

1	
	COUPLE OF OTHER ISSUES. AND CERTAINLY IF FOLKS HAVE
2	OTHER ISSUES, BUT LET'S KIND OF STAY ON THE SCORING
3	ONE FOR RIGHT NOW.
4	DR. STEWARD: I DO AND THEY ARE IN GENERAL
5	IN AGREEMENT WITH JEFF'S. BUT I'D REALLY LIKE TO
6	HEAR WHAT OTHER BOARD MEMBERS HAVE TO SAY BEFORE I
7	SORT OF REITERATE MY REINFORCEMENT OF WHAT YOU SAID
8	MAYBE WITH A COUPLE OF LITTLE QUIRKS.
9	DR. HIGGINS: I GUESS I'M A LITTLE
10	CONFUSED ABOUT THE DIFFERENCE BETWEEN AN 85 TO 100
11	RANGE VERSUS IF YOU HAD TWO 1S IN THE 1-2-3.
12	CHAIRMAN SHEEHY: I THINK FOR ME THE
13	RANKING BECOMES ARBITRARY.
14	DR. HIGGINS: SO IN OTHER WORDS, YOU WOULD
15	RATHER HAVE TWO 1S THAN HAVE AN 85 AND AN 87?
16	CHAIRMAN SHEEHY: YES. BECAUSE THEN THE
17	BOARD CAN KIND OF TEASE OUT WHAT THOSE DIFFERENCES
18	ARE. BUT THAT'S THE REASON WHY I WANT TO PUT IN A
19	POSTSCORING DISCUSSION, SO THAT THE BOARD MEMBERS
20	WHO ARE PARTICIPATING IN THAT CAN HAVE A CLEAR IDEA
21	OF WHAT THE ISSUES ARE THAT DISTINGUISH THE TWO
22	APPLICATIONS.
23	DR. STEWARD: LET ME JUST SAY ONE THING,
24	AND IT MAY BE IN PART AN ANSWER TO DAVID'S QUESTION.
25	THE REASON SO LET ME SAY FIRST OF ALL I WAS NOT A
<u>.</u>	11

1	FAN OF THE 1-2-3 SCORING SYSTEM WHEN FIRST PROPOSED.
2	I HAVE BECOME A FAN. AND WHOEVER THOUGHT THIS UP, I
3	DON'T KNOW WHETHER IT WAS RANDY OR GIL OR A
4	COMBINATION THEREOF, BUT IT REALLY HAS ONE MAJOR
5	STRENGTH. AND THAT IS THAT IT HAS ALLOWED AN
6	ITERATIVE IMPROVEMENT IN GRANTS. AND THE GRANTS
7	WORKING GROUP HAS WORKED ON THIS BASIS. SO THEY'LL
8	GIVE A 2 TO A GRANT THAT REALLY LOOKS GOOD, BUT IT'S
9	NOT QUITE THERE, IT COULD BE BETTER. I THINK RANDY
10	EXPLAINED IT BEST IN THE BEGINNING WHEN HE SAID THAT
11	WITH THIS SYSTEM, WE CAN MAKE GRANTS THAT WE FUND
12	95S OR ABOVES. GET THEM UP IN THE A CATEGORY RATHER
13	THAN FUNDING B GRANTS. THAT IS AN AMAZING STRENGTH.
14	I'VE SEEN IT WORK TO GREAT ADVANTAGE WITH THE
15	CLINICAL PROPOSALS.
16	SO THAT'S MY WHETHER IT'S 1-2-3 OR
17	WHATEVER, IT'S THAT MECHANISM THAT I'D LIKE TO SEE
18	PLACED ON THIS BECAUSE THIS IS A LOT OF MONEY AND
19	WE'RE ONLY DOING ONE OF THEM PRESUMABLY. IT'S THE
20	FIRST TIME WE'VE DONE ANYTHING LIKE THIS, SO I JUST
21	REALLY WOULD LIKE TO GET IT RIGHT. THAT'S ONE POINT
22	ABOUT THIS.
23	AGAIN, I DIDN'T MEAN TO JUMP IN BEFORE
24	OTHER BOARD MEMBERS SAID SOMETHING, BUT I DID WANT
25	TO MAKE THAT POINT.

1	CHAIRMAN THOMAS: I HAVE A QUESTION FOR
2	YOU. GIVEN THAT UNDER THE $1-2-3$ format, we give 2s
3	A CHANCE TO IMPROVE, ARE YOU SUGGESTING ON SOMETHING
4	LIKE THAT, LET'S SAY WE GOT ONE 1 AND ONE 2 IN THE
5	SCORING SYSTEM. WOULD YOU GIVE THE 2 A CHANCE TO
6	IMPROVE THE APPLICATION BEFORE IT GOES THE BOARD, OR
7	WOULD YOU GO STRAIGHT TO THE BOARD WITH THE 1 AS THE
8	RECOMMENDED FUNDING?
9	CHAIRMAN SHEEHY: I WOULD GO STRAIGHT TO
10	THE BOARD WITH THE 1. THAT WOULD BE MY VIEW.
11	CHAIRMAN THOMAS: OKAY. I AGREE WITH
12	THAT. SO I LIKE THE 1, 2, AND 3 ALSO. THE POINT
13	ONE THAT JEFF MADE THAT OS JUST REITERATED I AGREE
14	WITH. POINT TWO, I THINK THAT THE CHANCE TO HAVE,
15	SAY, TWO 1S EVALUATED ON EQUAL FOOTING RATHER THAN
16	TRYING TO DEFEND WHY YOU MIGHT END UP ULTIMATELY
17	TAKING AN 85 OVER AN 87 OR WHATEVER, WHICH IS TOO
18	CLOSE TO HAVE ANY REAL MATERIAL DIFFERENCE, I THINK
19	IT ALLOWS FOR DISCUSSION THAT DOESN'T HAVE
20	COLLATERAL ISSUES ATTACHED TO THE SECOND HIGHEST
21	VERSUS THE FIRST HIGHEST. IT GIVES THE BOARD EQUAL
22	FOOTING TO DISCUSS EVERYTHING, SO I'M IN FAVOR OF
23	THAT AS WELL.
24	CHAIRMAN SHEEHY: OTHER THOUGHTS FROM
25	OTHER BOARD MEMBERS?
	13

1	DR. VUORI: I AGREE WITH EVERYTHING WHAT
2	HAS BEEN SAID AND AS OUTLINED EARLIER.
3	CHAIRMAN SHEEHY: THANK YOU.
4	MR. PANETTA: I JUST THINK AS A BOARD
5	MEMBER WHO GETS TOTALLY CONFUSED BY THE
6	DISCREPANCIES IN NUMBERS BETWEEN 85, 88, 89, 83,
7	THAT SOMETHING MUCH MORE OBJECTIVE LIKE THIS MAKES
8	IT A LOT EASIER FOR ALL THE BOARD MEMBERS.
9	CHAIRMAN SHEEHY: THANK YOU. SO I HAVE
10	I DON'T KNOW IF YOU WANT TO SAY SOMETHING, SENATOR,
11	OR IF YOU HAVE A VIEW, BUT I THINK WE'VE HEARD FROM,
12	I THINK, EVERYBODY WHO'S HERE EXCEPT FOR YOU IF YOU
13	WANT TO EXPRESS AN OPINION.
14	MR. TORRES: YES. AS YOU KNOW, I ALWAYS
15	HAVE A VIEW.
16	CHAIRMAN SHEEHY: THANK YOU.
17	MR. TORRES: SO I JUST WANT TO REITERATE
18	MY SUPPORT FOR RANDY AND FOR GIL FOR ESTABLISHING
19	THIS NEW SYSTEM. I THINK IT'S WORKED TREMENDOUSLY.
20	I THINK IT HELPS US GET CLOSER TO TREATMENT BECAUSE
21	WE ACTUALLY HAVE AN OPPORTUNITY TO HELP SOME GRANTEE
22	THAT MAYBE IS CLOSE TO GETTING THERE AND JUST A FEW
23	ADDITIONAL COMMENTS OR SUPPORT CAN MAKE IT INTO A
24	MUCH BETTER PROPOSAL. SO I SUPPORT THE 1-2-3.
25	CHAIRMAN SHEEHY: SO, DR. MILLS, ARE YOU
	14
	14

1	GUYS COMFORTABLE WITH THAT GUIDANCE? OBVIOUSLY WE
2	CAN'T TAKE ACTION, BUT I'D HATE TO SEE US NOT
3	ALIGNED.
4	DR. MILLS: YEAH. SO, NO, IN GENERAL, WE
5	DON'T SHARE THAT POSITION FOR A COUPLE OF REASONS.
6	ONE IS I DON'T KNOW HOW A BOARD WHICH ISN'T PRESENT
7	FOR THE INTERNAL DISCUSSION IS GOING TO BE ABLE TO
8	SEPARATE OUT TWO 1S, ONE OF WHICH MIGHT HAVE BEEN AN
9	85 AND ONE OF WHICH MIGHT HAVE BEEN A 95 WITH LESS
10	INFORMATION.
11	AND, TWO, I JUST HAVE A PRACTICAL CONCERN
12	ABOUT A 2 IN ATP3. AND THAT CENTERS AROUND IF
13	SOMEBODY PUTS TOGETHER A BUSINESS PLAN AND SOMEBODY
14	PULLS TOGETHER A MANAGEMENT TEAM AND SOMEBODY LINES
15	UP \$75 MILLION IN FUNDING, THE LIKELIHOOD THAT
16	THEY'LL BE ABLE TO HOLD ALL OF THAT TOGETHER FOR A
17	PROTRACTED DELAY, JUST IN PRACTICAL TERMS, IS
18	RELATIVELY SMALL.
19	WITH ALL OF THAT SAID, I THINK IT WILL
20	WORK EITHER WAY JUST FINE. SO THAT'S WHY WE
21	PROPOSED THIS METHOD, BUT WE ARE COMPLETELY FINE
22	WITH 1-2-3. WE HAVE NO OBJECTION TO IT.
23	CHAIRMAN SHEEHY: SO HOW SHALL WE LEAVE
24	THIS THEN?
25	DR. MILLS: IT'S UNANIMOUS. WE FOLLOW THE
	15

1	
1	BOARD. SO WE'LL ADOPT 1-2-3.
2	CHAIRMAN SHEEHY: THANK YOU.
3	AND THEN I WAS GOING TO GO AHEAD AND RAISE
4	MY OTHER TWO ISSUES, BUT DO OTHER FOLKS HAVE ISSUES?
5	I DON'T WANT TO MONOPOLIZE THIS.
6	SO MY OTHER ISSUE IS ON THE SPECIALISTS.
7	AND I THINK CAN I KIND OF DISCUSS CANDIDLY WHAT I
8	WAS THINKING? SO WE HAVE HAD SEVERAL BOARD MEMBERS
9	FROM INDUSTRY WHOSE SERVICE HAS BEEN EXTRAORDINARY.
10	AND SO MY HOPE WAS THAT WE WOULD REACH OUT TO THEM.
11	THEY'VE DEMONSTRATED A COMMITMENT, NOT ONLY TO CIRM,
12	BUT TO THE STATE OF CALIFORNIA, AND THEIR SERVICE
13	WAS PERFORMED WITH THE HIGHEST STANDARDS OF
14	INTEGRITY. FOR ME PERSONALLY, I MAY BE IN THE WOODS
15	A BIT, ESPECIALLY AS WE START TALKING ABOUT THE
16	BUSINESS ASPECTS OF THIS, SO FOR ME I REALLY WANT TO
17	ENCOURAGE CIRM TO REACH OUT TO THOSE FORMER BOARD
18	MEMBERS. THEIR PARTICIPATION WOULD GIVE ME AN
19	INCREDIBLE DEGREE OF CONFIDENCE IN THE OUTCOMES THAT
20	WE OBTAIN.
21	SO THAT IS THE I JUST WANTED TO MAKE
22	THAT COMMENT AND ENCOURAGE THOSE KINDS OF EFFORTS.
23	CHAIRMAN THOMAS: YOU AND I TALKED ABOUT
24	THIS. I AGREE WITH YOU COMPLETELY. AS YOU KNOW,
25	WE'RE REACHING OUT TO THEM TO SEE IF WE CAN ACHIEVE
	16
	τυ

1	PRECISELY THAT RESULT.
2	CHAIRMAN SHEEHY: THANKS, J.T.
3	AND THEN JUST THE OTHER THING, AND JUST
4	THROWING THIS IN SINCE WE'RE HAVING THIS DISCUSSION,
5	WE'RE GOING TO DO THIS TOMORROW, BUT JUST TO PUT OUT
6	THERE FOR THE FUTURE, IF WE HAVE WINNERS, SO TO
7	SPEAK, I THINK IT WOULD BE VERY USEFUL TO HAVE THEM
8	PRESENT TO THE BOARD. WE HAVE THE SUCCESSFUL
9	ACCELERATING CENTER APPLICANT COMING. BECAUSE
10	THEY'RE PRESENTING AT THE GWG, I THINK IT'S VERY
11	HELPFUL TO HAVE THEM ALSO PRESENT TO THE BOARD SINCE
12	THEY'VE ALREADY DONE A PRESENTATION. AND IT'S A
13	GREAT WAY TO, FIRST OF ALL, EDUCATE US AS BOARD
14	MEMBERS ON WHAT WE'RE ACTUALLY DOING. I THINK IT
15	STANDS AS A IT REALLY MAKES YOU FEEL GREAT ABOUT
16	THE CIRM TEAM, AND IT REALLY HELPS YOU RECOGNIZE
17	INCREDIBLY HARD WORK THAT THE CIRM TEAM HAS DONE IN
18	CREATING THESE INNOVATIVE PROGRAMS, BUT ALSO
19	EDUCATES THE PUBLIC AND LET'S THEM KNOW WHAT WE'RE
20	DOING AND INCREASES THEIR LITERACY ABOUT CIRM.
21	THOSE WERE ALL OF MY ISSUES THAT I HAD.
22	LIKE I SAID, IF OTHER PEOPLE HAVE ISSUES, BUT THOSE
23	WERE MY RECOMMENDATIONS.
24	SO UNLESS SOMEBODY HAS SOMETHING ELSE, IS
25	THERE ANY OTHER BUSINESS, ANY PUBLIC COMMENT? SHALL
	17

1	WE ADJOURN? DR. STEWARD.
2	DR. STEWARD: WE DO NOT HAVE A QUORUM.
3	MR. SHEEHY: GREAT. I WANT TO THANK
4	EVERYBODY. I'M SURE WE'LL SEE MANY OF YOU TOMORROW.
5	SAFE TRAVELS IF YOU'RE TRAVELING. THANK YOU.
6	(THE MEETING WAS THEN CONCLUDED AT
7	04:25 PM.)
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	18
16	0 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE JOINT MEETING OF THE SCIENCE SUBCOMMITTEE AND THE IP AND INDUSTRY SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

CLAREMONT HOTEL 44 TUNNEL ROAD BERKELEY, CALIFORNIA ON JUNE 14, 2016

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTERS' REPORTING SERVICE 160 S. OLD SPRINGS ROAD SUITE 270 ANAHEIM, CALIFORNIA (714) 444-4100